CB
CBSTF
Cannabist Co Holdings Inc.
No data for this timeframe.
Vol
SEC Reports3
Recent Activity
May 8, 2026
SEC
Cannabist completed the sale of its Delaware assets for $16.5 million amid ongoing CCAA restructuring proceedings. The c
8-K — Impact 9/10
Apr 7, 2026
SEC
Jesse Channon, President of Cannabist Co Holdings Inc., resigned as an employee effective April 1, 2026, and transitione
8-K — Impact 3/10
Mar 19, 2026
SEC
The Cannabist Company Holdings Inc. announced that an ad hoc group of noteholders has agreed to extend their forbearance
8-K — Impact 6/10
Price Targets
Historical data — last covering-analyst action Aug 2024. No current recommendation available.
$0.6265 (Aug 2024)
Current $0.0291
Low $0.5030
Median $0.6265
High $0.7500
2 analysts
$0.5030
$0.7500
Analyst Ratings
0Strong Buy
0Buy
3Hold
4Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 12, 2024 | Needham | REITERATE | Hold |
| Mar 15, 2024 | Roth MKM | MAINTAIN | Buy → Buy |
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
BEARISH
8-K
9/10
Cannabist completed the sale of its Delaware assets for $16.5 million amid ongoing CCAA restructurin
May 8, 2026
NEUTRAL
8-K
3/10
Jesse Channon, President of Cannabist Co Holdings Inc., resigned as an employee effective April 1, 2
Apr 7, 2026
BEARISH
8-K
6/10
The Cannabist Company Holdings Inc. announced that an ad hoc group of noteholders has agreed to exte
Mar 19, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Aug 2024): 0% buy across 9 analysts — 0 strong buy, 0 buy, 3 hold, 4 sell, 2 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Aug 2024. No current recommendation available.
$0.6265 mean target (Aug 2024)
$0.5030 Low
$0.7500 High
| Metric | Value |
|---|---|
| Current Price | $0.0291 |
| Target Low | $0.5030 |
| Target Mean | $0.6265 |
| Target Median | $0.6265 |
| Target High | $0.7500 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 12, 2024 | Needham | REITERATE | — | Hold |
| Mar 15, 2024 | Roth MKM | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 3 | 4 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 4 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 4 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 4 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 4 | 4 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 4 | 4 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.